. Author manuscript; available in PMC: 2009 Jul 17.

Published in final edited form as: Graefes Arch Clin Exp Ophthalmol. 2008 Apr 11;246(7):1029–1046. doi: 10.1007/s00417-008-0805-8

Table 10.

Comparison of percent improvement in visual field defect^* between those with initial moderate to severe visual field defect and were seen within 2 weeks of NA-AION onset who received steroid therapy within 2 weeks of onset and those that did not receive any steroid

Follow-up period	Percent with improved visual field^* (95% confidence interval)		Odds ratio (95% CI) for VF improvement (steroid/no steroid)	p value
	Steroid	No steroid^**	Odds ratio (95% CI) for VF improvement (steroid/no steroid)	p value
At ODE resolution	36.6% (29.7%, 43.9%)	19.6% (13.8%, 27.0%)	2.36 (1.41, 3.96)	0.001
3 months from first visit	37.7% (30.8%, 45.0%)	19.7% (13.9%, 27.2%)	2.47 (1.48, 4.12)	0.0006
6 months from first visit	40.1% (33.1%, 47.5%)	24.5% (17.7%, 32.9%)	2.06 (1.24, 3.40)	0.005
1 year from first visit	40.0% (33.0%, 47.3%)	24.7% (17.8%, 33.1%)	2.03 (1.23, 3.36)	0.006

Estimates obtained from the repeated measures logistic regression model fitted using the generalized estimating equations (GEE) method

^**

From cohort of patients in our natural history study of NA-AION [28]

CI = Confidence interval; NA-AION = Non-arteritic anterior ischemic optic neuropathy; ODE = Optic disc edema; VF = Visual field